Background: Cryptococcal meningitis (CM) is the most common cause of AIDS-related mortality in sub-Saharan Africa. CM accounts for between 33% and 63% of all adult meningitis within that region and is responsible for over 500,000 deaths annually; more AIDS-related deaths than tuberculosis. In sub-Saharan Africa, the WHO recommends routinely screening AIDS patients with a CD4 T-cell count less than 100 cells/μl for cryptococcal infection and initiating anti-cryptococcal therapy to prevent CM. The prevalence at which routine cryptococcal infection was found to be cost-effective was 2%. In the United States however there are no such screening recommendations because there is a lack of prevalence data and thus no opportunity for a costeffective analysis. We aimed to determine the prevalence of cryptococcal infection among advanced AIDS patients in the United States to guide potential updates in the prevention and management of CM. Methodology: Using stored sera from the Multicenter AIDS Cohort Study and the Women’s Interagency HIV Study, we screened specimens from 1,872 participants with CD4 T-cell counts less than 100 cell/μl for cryptococcal infection. We tested serum from participants using the CrAg Lateral Flow Assay (Immy, Inc. Norman, OK), a FDA-cleared test for the detection of cryptococcus antigen (CrAg). Results: The overall prevalence of CrAg positivity within this population was 2.9% (CI: 0.2-3.8%). The table below describes the results of CrAg positivity by gender, geographical location, and time (pre -HAART and post- HAART). Due to restrictions in table length, Baltimore (3.0%,CI:1.5-6.0%), Chicago (2.3%, CI:0.8-6.8%), and Brooklyn (1.9%, CI:0.6-5.3%) were not included in the table below. Conclusions: Presently, routine screening for cryptococcal infection is only recommended in AIDS patients with a CD4 less than 100 cell/ul in sub- Saharan Africa. The results from this study suggest the prevalence of cryptococcal infection in the United States is above published cost-effective threshold, varies regionally and may warrant routine screening to detect early infection.